4 May 2016 - Eli Lilly announced today that the U.S. FDA has granted priority review for the biologics license application for olaratumab, a PDGFRα antagonist, in combination with doxorubicin, for the potential treatment of people with advanced soft tissue sarcoma not amenable to curative treatment with radiotherapy or surgery.

Lilly has received additional designations for olaratumab from the FDA, including breakthrough therapy, fast track and orphan drug for this indication.

Lilly also submitted olaratumab to the EMA in the first quarter of 2016, and the application is currently being reviewed under an accelerated assessment schedule.

For more details, go to: https://investor.lilly.com/releasedetail.cfm?ReleaseID=969023